Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eckert & Ziegler SECHIX:EUZD 94 5-Year ROIIC % is 20.39 as of Dec. 2025. GuruFocus rates CHIX:EUZD with a GF Score™ of 94/100 and a GF Value™ of €16.40 (Fairly Valued). Among 733 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks better than 74.22% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Eckert & Ziegler SE's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 20.39%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Eckert & Ziegler SE's 5-Year ROIIC % or its related term are showing as below:
CHIX:EUZd's 5-Year ROIIC % is ranked better than 74.22% of 733
companies
in the Medical Devices & Instruments industry
Industry Median: 0.92
vs CHIX:EUZd: 20.39
Eckert & Ziegler SE (CHIX:EUZd) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Eckert & Ziegler SE 5-Year ROIIC % Related Terms
Eckert & Ziegler SE 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:EUZD vs ABT, SYK, MDT: 5-Year ROIIC % Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE 5-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's 5-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Eckert & Ziegler SE (CHIX:EUZD) has a 5-Year ROIIC % of 20.39 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Eckert & Ziegler SE and its competitors. According to the industry distribution chart, Eckert & Ziegler SE ranks #189 out of 733 companies in the Medical Devices & Instruments industry, placing it in the top 25.8%.
Is Eckert & Ziegler SE's 5-Year ROIIC % too high?
Eckert & Ziegler SE's current 5-Year ROIIC % is 20.39. The Medical Devices & Instruments industry median 5-Year ROIIC % is 0.92. Eckert & Ziegler SE's value of 20.39 is 2116.3% above this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #189 out of 733 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Eckert & Ziegler SE has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's 5-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #189 out of 733 companies for 5-Year ROIIC %. This puts Eckert & Ziegler SE in the upper half of its industry. The industry median 5-Year ROIIC % is 0.92. Eckert & Ziegler SE's value of 20.39 is 2116.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Medical Devices & Instruments company?
The median 5-Year ROIIC % among Medical Devices & Instruments companies is 0.92, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current 5-Year ROIIC % of 20.39 is 2116.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median 5-Year ROIIC % is 0.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current 5-Year ROIIC % is 20.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (CHIX:EUZD) is currently considered Fairly Valued. The stock's GF Value™ is €16.40, compared to a current price of €15.19 — trading 7.4% below its estimated fair value. The current 5-Year ROIIC % is 20.39 and 2116.3% above the Medical Devices & Instruments industry median of 0.92. Eckert & Ziegler SE's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Eckert & Ziegler SE (CHIX:EUZD), the current 5-Year ROIIC % is 20.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.19 is trading 7.4% below its estimated GF Value™ of €16.40.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for CHIX:EUZD:
5-Year ROIIC %: 20.39
GF Value™: €16.40 vs. price of €15.19 (7.4% below fair value)
Industry Position: 2116.3% above the Medical Devices & Instruments median (#189 of 733)
No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
94GF Score
Get the complete analysis for CHIX:EUZD
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EUZD has been successfully added to your 
